

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M.10825 - DAVITA / MEDTRONIC / MEDTRONIC RENAL CARE SOLUTIONS SECTION 1.2

Description of the concentration

On 16 January 2023, the European Commission received a notification of a proposed concentration pursuant to which Medtronic, Inc. and relevant group companies (Medtronic) and DaVita Inc.(DaVita) will establish joint control over Medtronic's Renal Care Solutions business (RCS business), within the meaning of Article 3 (4) of Council Regulation (EC) No 139/2004 of 20 January 2004.

DaVita provides kidney dialysis services through a network of outpatient dialysis centres. DaVita primarily treats end-stage renal disease (ESRD), which requires patients to undergo dialysis three times per week for the rest of their lives unless they receive a donor kidney.

Medtronic is a global healthcare technology company dedicated to searching out and finding solutions to the most challenging human health problems.

The RCS business is active in the research, development, manufacture, license, commercialization and distribution and sale of renal care products and other medical devices used in the treatment of patients with ESRD (including dialysis machines, related items used in connection with dialysis treatments, catheters and other devices used in connection with the creation or maintenance of vascular access).